Clinical trials
Marginal Zone Lymphoma clinical trials
Below are recruiting marginal zone lymphoma clinical trials, each written for real people, not researchers. We’re tracking 84 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06905509RecruitingPhase 2
Epcoritamab with chemo and stem cell transplant for large B-cell lymphoma
This trial tests adding epcoritamab (an immune therapy that helps your body fight cancer) to standard chemotherapy followed by a stem cell transplant. It is for people with large B-cell lymphoma that has come back or not responded to initial treatment.
Sacramento, CaliforniaAges 18 years+ - NCT07173790Enrolling by invitation
Watch and Wait in Slow-Growing Lymphoma
This study looks at how people with slow-growing lymphomas (like CLL, MZL, FL, or WM) feel during watchful waiting — when they are not on active treatment. It aims to see if patients are more anxious or worried, and how to best support them.
Seoul, Gangnam-guAges 19 years+ - NCT07168486Enrolling by invitationPhase 1
CAR T-cells targeting CD19, CD20, and CD22 for lymphoma
This trial tests a new type of CAR T-cell therapy that targets three proteins (CD19, CD20, and CD22) on lymphoma cells. It's for people with B-cell lymphomas that have come back or not responded to at least two prior treatments.
Baltimore, MarylandAges 18 years+ - NCT06134284RecruitingPhase 4
Ibrutinib plus rituximab for refractory MZL
This trial tests a new combination of two drugs (ibrutinib and rituximab) for people with marginal zone lymphoma that has not responded to other treatments. The goal is to see if this combination can help shrink the lymphoma and improve outcomes.
Hangzhou, ZhejiangAges 18–80 - NCT06449885Recruiting
Observational study for newly diagnosed MZL
This study is for people who were just diagnosed with marginal zone lymphoma (a slow-growing blood cancer) and haven't started treatment yet. Researchers will collect blood and tissue samples and follow you over time to learn more about the disease.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06700798RecruitingPhase 2
Orelabrutinib plus rituximab vs R-CVP for untreated MZL
This trial tests a new combination of two drugs (orelabrutinib and rituximab) compared to the standard R-CVP chemotherapy for people with newly diagnosed marginal zone lymphoma. The goal is to see which approach works better and has fewer side effects.
Nanchang, JiangxiAges 18 years+ - NCT06793189RecruitingPhase 2
Risk-Adapted Targeted Therapy for Untreated MZL
This trial tests a personalized treatment plan for people with newly diagnosed marginal zone lymphoma (MZL). The treatment is based on a risk score and aims to be more targeted than standard chemotherapy.
Shanghai, ChinaAges 18 years+ - NCT07208981RecruitingPhase 2
Orelabrutinib, zebetuzumab, and lenalidomide for new MZL
This trial tests a combination of three drugs (orelabrutinib, zebetuzumab, and lenalidomide) for people newly diagnosed with a type of lymphoma called marginal zone lymphoma (MZL). If you qualify, you may receive this treatment to help control the disease.
Nanjing, JiangsuAges 18–75 - NCT07372365RecruitingPhase 2
Orelabrutinib after initial therapy for new marginal zone lymphoma
This trial tests an oral medication called orelabrutinib as a follow-up treatment after initial therapy for marginal zone lymphoma that hasn't been treated yet. The goal is to see if it helps keep the lymphoma from coming back.
Suzhou, JiangsuAges 18 years+ - NCT07441993RecruitingPhase 2
Orelabrutinib for early-stage untreated marginal zone lymphoma
This trial tests an oral targeted therapy (orelabrutinib) for people with early-stage marginal zone lymphoma who have not yet had treatment. The goal is to see if this medication can control the cancer with fewer side effects than standard treatments.
Guangzhou, GuangdongAges 18 years+ - NCT07448324RecruitingPhase 2
Orelabrutinib plus rituximab with or without lenalidomide for untreated MZL
This trial tests a combination of targeted drugs for people with a type of lymphoma called marginal zone lymphoma (MZL) that has not been treated before. The drugs attack cancer cells in different ways, and the treatment plan may adjust based on how you respond.
Nanjing, JiangsuAges 18 years+ - NCT05633615RecruitingPhase 2
Testing new drug options after CAR T for aggressive lymphoma
This Phase 2 study tests whether adding or switching drug treatments after CAR T-cell therapy can improve outcomes for people with certain aggressive lymphomas that have come back or did not respond. It mainly looks at who remains disease-stable/partly improved after CAR T and what treatment approach works best next.
Tucson, ArizonaAges 18 years+
Hear when a new Marginal Zone Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for marginal zone lymphoma?
- Yes. Clin2 currently lists 84 recruiting marginal zone lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a marginal zone lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a marginal zone lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.